Drugdocs | Vizimpro

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Vizimpro

Chemical Name	dacomitinib
Dosage Form	Tablet (oral; 15 mg, 30 mg, 45 mg)
Drug Class	Kinase inhibitors
System	Respiratory
Company	Pfizer Inc.
Approval Year	2018

Indication

To treat of metastatic non-small cell lung cancer in cases with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations preceeding the use of other therapies.

Last updated on 3/10/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Vizimpro (Dacomitinib) Prescribing Information	2018	Pfizer Inc., New York, NY

Document Title	Year	Source
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer.	2019	NICE

Document Title	Year	Source
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: Systematic review and network meta-analysis.	2020	BMJ
Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis.	2020	Lung Cancer Management
First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: A network meta-analysis.	2019	OncoTargets and Therapy

Document Title	Year	Source
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.	2019	International Journal of Clinical Oncology
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).	2018	Clinical and Translational Oncology